Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.

about

Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.

Item

http://www.wikidata.org/entity/Q47556203

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Thyroid disorders in alemtuzum ...... s on diagnosis and management.

@en

Thyroid disorders in alemtuzum ...... s on diagnosis and management.

@nl

type

Item

label

Thyroid disorders in alemtuzum ...... s on diagnosis and management.

@en

Thyroid disorders in alemtuzum ...... s on diagnosis and management.

@nl

prefLabel

Thyroid disorders in alemtuzum ...... s on diagnosis and management.

@en

Thyroid disorders in alemtuzum ...... s on diagnosis and management.

@nl

P1476

Thyroid disorders in alemtuzum ...... us on diagnosis and management

@en

P2093

Bart Van Wijmeersch

http://www.w3.org/2001/XMLSchema#string

Chantal Daumerie

http://www.w3.org/2001/XMLSchema#string

Emmanuel Bartholomé

http://www.w3.org/2001/XMLSchema#string

Miguel D'haeseleer

http://www.w3.org/2001/XMLSchema#string

Pierrette Seeldrayers

http://www.w3.org/2001/XMLSchema#string

Souraya El Sankari

http://www.w3.org/2001/XMLSchema#string

Valérie Delvaux

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical Relevance of Environmental Factors in the Pathogenesis of Autoimmune Thyroid Disease

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis

Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.

Antithyroid drugs.

P2888

s13760-018-0883-2

P304

153-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13760-018-0883-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Brigitte Decallonne

P577

2018-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29372482

http://www.w3.org/2001/XMLSchema#string

P932

5971042

http://www.w3.org/2001/XMLSchema#string